RT Journal Article
SR Electronic
T1 ▾ Etodolac - a new NSAID for rheumatoid arthritis
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 11
OP 12
DO 10.1136/dtb.25.3.11
VO 25
IS 3
YR 1987
UL http://dtb.bmj.com/content/25/3/11.abstract
AB Etodolac (Lodine-Ayerst; Ramodar-Wyeth) is the first new non-steroidal anti-inflammatory drug (NSAID) to be licensed in Britain for over three years. The licence is for use in rheumatoid arthritis (RA) only. Etodolac is claimed to be as effective as high-dose aspirin with no more unwanted effects than placebo. Does the clinical evidence support this claim?